Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radiation technique targets spine tumors to zap pain

NCT ID NCT00508443

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests a highly precise radiation system (CT-on-Rails or Trilogy) to treat spine tumors that have spread from other cancers. About 150 participants will receive three radiation sessions over two weeks. Researchers will track pain relief and side effects using patient questionnaires to see if this approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (stereotactic spine radiotherapy using CT-on-Rails or Trilogy system)
What this could lead to
If successful, this could offer a more precise and effective way to relieve pain from spine tumors, improving quality of life for cancer patients.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 150 participants, so results may not apply to everyone. Side effects from radiation are possible, and pain relief may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2002

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Radiographically documented spine or paraspinal metastasis demonstrated on spine MRI within 4 wks of registration 2. Maximum of 2 metastatic sites in the spine to be irradiated over a single course of treatment. 3. Informed consent for irradiation or re-irradiation of spinal or para-spinal tumor (s) 4. Diagnosis cancer including but not limited to lung (non-small cell and small cell), breast, prostate, renal cell, melanoma, gastrointestinal, germ cell tumors, and unknown primary tumors 5. Karnofsky performance status of at least 40 (i.e. not requiring active hospitalization) 6. Maximum of 1 prior course of spine radiotherapy to the current region of interest allowed. Exclusion Criteria: 1. Worsening neurological status due to radiographic evidence of spinal cord compression requiring immediate surgical decompression or emergent conventional external radiation therapy 2. Delay in initiation of radiation treatment would be potentially detrimental to neurological outcome 3. Patients already re-treated with radiation as part of this protocol will not be eligible for additional re-treatment 4. Unstable spine requiring surgical stabilization. 5. Sites outside the spine (eg. lung, liver) are not eligible for treatment 6. Systemic radiotherapy (Sr-89) within 30 days 7. Prior irradiation of the area to be treated within 3 months of registration 8. Patients currently receiving, or who have received chemotherapy within 30 days are not eligible 9. Inability to tolerate lying flat on treatment couch for greater than 30 minutes. 10. Patient with multiple myeloma 11. Patients unable to undergo MRI of the spine 12. Patients with pacemakers 13. Patients who have previously received maximum cord tolerance of 45 Gy in 5 weeks conventional fractionation or equivalent dose to the current area to be treated.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic spine disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.